Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer
Mario I. Fernández(Clínica Alemana), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Rebecca Slack, Edmund Chiong(The University of Texas MD Anderson Cancer Center), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Louis L. Pisters(The University of Texas MD Anderson Cancer Center), Jay B. Shah(The University of Texas MD Anderson Cancer Center), Stephen B. Williams(Cedars-Sinai Medical Center), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), David J. McConkey(Johns Hopkins University), Bogdan Czerniak(The University of Texas MD Anderson Cancer Center), Sahil Parikh(The University of Texas MD Anderson Cancer Center), Rian J. Dickstein(Chesapeake Urology Associates), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Daniel Willis(The University of Texas MD Anderson Cancer Center), Charles C. Guo(The University of Texas MD Anderson Cancer Center)
Cited by 46
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k